A major contributor to the lack of medicines in developing countries is an intellectual property regime that allows proprietary drug companies with intellectual property monopolies to charge high prices and maximize profit.
After years of funding disease-specific treatment, donation trends have shifted to support broader health systems infrastructure development. A remaining challenge is how to sustain antiretroviral therapy (ART) for patients in resource-poor regions.
AMA J Ethics. 2016;18(7):681-690. doi:
10.1001/journalofethics.2016.18.7.ecas3-1607.
Judgmentalism applied to patients from poor and marginalized communities exacerbates health inequity and illuminates the importance of contextualizing a patient’s care.
AMA J Ethics. 2021;23(2):E91-96. doi:
10.1001/amajethics.2021.91.
Some refugees’ illness experiences preclude them from testifying and accurately representing their own interests during asylum adjudication proceedings.
AMA J Ethics. 2021;23(2):E132-139. doi:
10.1001/amajethics.2021.132.
Long-acting injectables powerfully augment HIV care, but broad acceptance and uptake could be compromised by what we know about experiences with antipsychotics.
AMA J Ethics. 2021;23(5):E405-409. doi:
10.1001/amajethics.2021.405.
Rayner Kay Jin Tan, Jane Mingjie Lim, MSW, and Jeremiah Kah Wai Chan, MSc
Merits and drawbacks of U = U messaging are ethically and clinically complex, and drawbacks could harm patients in whom viral suppression is hard to achieve.
AMA J Ethics. 2021;23(5):E418-422. doi:
10.1001/amajethics.2021.418.